If you have been reading about IGF-1 marker and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
== Other uses == Put/call ratio, in finance Amdo Tibetan (ISO 639 code pcr), a language Germán Olano Airport (IATA code PCR), Colombia Palestinian Center for Rapprochement between Peoples, Palestine Pancritical rationalism, a development of critical rationalism and panrationalism Paul Cruickshank Racing, an Australian motor racing team Police control room, an emergency control centre Practical Chinese Reader, a textbook Production control room, of a television studio Princess Connect! Re:Dive, a video game Police of the Czech Republic Pavement Classification Rating Post-consumer resin, a blend of reclaimed natural HDPE and virgin resin
=== Casting === Upon the pilot order announcement, Bates was cast to star. Skye P. Marshall, Jason Ritter, David Del Rio, and Leah Lewis joined the main cast upon the series order announcement. On February 8, 2024, Beau Bridges was cast in a recurring capacity. On April 1, 2024, Yael Grobglas joined the cast in a recurring role. In August 2024, Andrea Londo and Piper Curda were cast in recurring capacities. On September 8, 2024, Bates said that Matlock was to be her final role before retirement. On October 9, 2024, she walked it back, saying that "I think that they got a bit confused." On August 1, 2025, Justina Machado joined the cast in a recurring role for the second season. On October 9, 2025, it was reported that Del Rio had been fired due to a sexual assault allegation involving Lewis. On December 11, 2025, Henry Haber and Sarah Wright Olsen were cast in recurring capacities for the second season.
=== Medical insurance coverage === Insurance companies in the United States typically require the physician to provide evidence that a woman's large breasts cause headaches or back and neck pain before they will pay for breast reduction. Insurance companies also mandate a woman who is overweight, which is often the case with gigantomastia, to first lose a certain amount of weight. They also commonly require the patient to try alternative treatments like physical therapy for a year or more.
Analyses of NYTS data indicate that the decline observed between 2023 and 2024 was primarily driven by reductions among high school students. The same report noted that disparities persist, with increased in tobacco product use observed in some groups. US federal reporting has also described a longer-term pattern in which e-cigarette use among young people peaked in 2019 and declined substantially by 2024; during this period, regulatory and enforcement actions against unauthorized e-cigarette products were expanded. Data from other countries provide additional comparisons. In Great Britain, a 2024 ASH/YouGov youth survey reported that vaping among 11-17 year olds appears to have stabilized after earlier increases (ever-use 18% in 2024 compared with 20% in 2023). The same survey reported current vaping at 7.2% among 11-17 year olds (including less-than-monthly use). Additionally, UK reporting has described proposals in the Tobacco and Vapes Bill, including restrictions aimed at reducing youth uptake. Following 2024 UK survey results, the Royal College of Pediatrics and Child Health called for measures including restrictions on disposable e-cigarettes, flavors, and advertising to reduce youth uptake. In Canada, there was a trend showing 29% of young people reporting to have used e-cigarettes in 2017, increasing to 37% in 2018. In New Zealand, school survey data indicated that regular and daily vaping had declined by 2024 after peaking in 2021 and the 2024/25 the New Zealand Health Survey reported that daily smoking had reduced to below 5.0% among people aged 15–24.
In archaeology, the term in situ has been used variably to describe artifacts or features found undisturbed since deposition; however, its definition remains contested. Scholars distinguish between a broad usage, referring to materials recovered through controlled excavation, and a stricter usage applied only to those discovered in undisturbed depositional settings. Between these poles lies a continuum of depositional scenarios, from sealed habitation floors to slope or fluvial deposits, meaning that whether an object is in situ depends on site-specific formation processes and the degree to which stratigraphic—as well as spatial—relationships can be reconstructed. Recording the exact spatial coordinates, stratigraphic position, and surrounding matrix of depositional materials is necessary for understanding past human activities and historical processes. While artifacts are often removed for analysis, certain archaeological features—such as hearths, postholes, and architectural foundations—have to be thoroughly documented in place to preserve their contextual information during excavation. This documentation relies on various methods, including detailed field notes, scaled technical drawings, cartographic representation, and high-resolution photographic records. Current archaeological practice incorporates advanced digital technologies, including 3D laser scanning, photogrammetry, unmanned aerial vehicles, and Geographic Information Systems (GIS), to capture complex spatial relationships.
Sources: en.wikipedia.org
== Real-time air monitoring == The first SCIEX product, introduced in 1979, was the TAGA (Trace Atmospheric Gas Analyzer) quadrupole mass spectrometer system, which used atmospheric-pressure chemical ionization (APCI) for direct air analysis. Use of a cryopump vacuum system run by a liquid helium compressor allowed the instrument to be mounted in a large van for mobile operation, and operated while in motion to monitor concentrations of air pollutants. In 1981, the TAGA 6000, the first commercial triple quadrupole mass spectrometer, was introduced also in both lab-based and mobile configurations. Systems were acquired by, among others, government environmental agencies in Ontario and New York State, and the USEPA, and have been used in various applications such as tracking fugitive emission plumes from industrial sites, analysis of gases from contaminated homes in the Love Canal area and for air monitoring in the Gulf area after the BP spill in 2010. In 1979, the TAGA 3000 was used for real-time monitoring of toxic gas plumes of chlorine, styrene and other gases released from the Mississauga train derailment and fire providing timely information for emergency personnel.
== Preparation and manufacturing == The simplest method for preparing ceramic superconductors is a solid-state thermochemical reaction involving mixing, calcination and sintering. The appropriate amounts of precursor powders, usually oxides and carbonates, are mixed thoroughly using a Ball mill. Solution chemistry processes such as coprecipitation, freeze-drying and sol–gel methods are alternative ways for preparing a homogeneous mixture. These powders are calcined in the temperature range from 1,070 to 1,220 K (800 to 950 °C) for several hours. The powders are cooled, reground and calcined again. This process is repeated several times to get homogeneous material. The powders are subsequently compacted to pellets and sintered. The sintering environment such as temperature, annealing time, atmosphere and cooling rate play a very important role in getting good high-Tc superconducting materials. The YBa2Cu3O7−x compound is prepared by calcination and sintering of a homogeneous mixture of Y2O3, BaCO3 and CuO in the appropriate atomic ratio. Calcination is done at 1,070 to 1,220 K (800 to 950 °C), whereas sintering is done at 1,220 K (950 °C) in an oxygen atmosphere. The oxygen stoichiometry in this material is very crucial for obtaining a superconducting YBa2Cu3O7−x compound. At the time of sintering, the semiconducting tetragonal YBa2Cu3O6 compound is formed, which, on slow cooling in oxygen atmosphere, turns into superconducting YBa2Cu3O7−x. The uptake and loss of oxygen are reversible in YBa2Cu3O7−x.
== Motivation == Researcher Frederick Banting famously refused to put his name on the patent after discovering insulin in 1923. The original patent for insulin was later sold by his collaborators for just $1 to the University of Toronto in an effort to make it as available as possible. Despite this, for various reasons, there remains no generic version of insulin available in the US. Insulin remains controlled by a small number of large pharmaceutical companies and sold at prices unaffordable to many who rely on it to live, particularly those without insurance. This lack of availability has led to fatalities, such as Alec Smith, who died in 2017 due to lack of insulin. The Open Insulin Project is motivated by the urgent need to protect the health of those with diabetes regardless of their economic or employment status by developing low-cost methods for insulin production available for anyone to use.
This is one reason why extreme intakes of any one single micronutrient are not advised. Individuals with chronic digestive problems may be unable to absorb sufficient amounts of copper, even though the foods they eat are copper-rich. Several copper transporters have been identified that can move copper across cell membranes. Other intestinal copper transporters may exist. Intestinal copper uptake may be catalyzed by Ctr1. Ctr1 is expressed in all cell types so far investigated, including enterocytes, and it catalyzes the transport of Cu+1 across the cell membrane. Excess copper (as well as other heavy metal ions like zinc or cadmium) may be bound by metallothionein and sequestered within intracellular vesicles of enterocytes (i.e., predominant cells in the small intestinal mucosa).
Sources: en.wikipedia.org
It may lead to brain tumors such as astrocytomas. In some of the late-onset neurodegenerative diseases that share aggregation of misfolded proteins as a common feature, such as Parkinson's disease and Alzheimer's disease, large insoluble aggregates of misfolded proteins can form and then result in neurotoxicity, through mechanisms that are not yet well understood. Decreased proteasome activity has been suggested as a cause of aggregation and Lewy body formation in Parkinson's. This hypothesis is supported by the observation that yeast models of Parkinson's are more susceptible to toxicity from α-synuclein, the major protein component of Lewy bodies, under conditions of low proteasome activity. Impaired proteasomal activity may underlie cognitive disorders such as the autism spectrum disorders, and muscle and nerve diseases such as inclusion body myopathy.
== Biography == Macleod was born in Clunie, near Dunkeld in Perthshire. Soon after he was born, his father Robert Macleod, a minister of the Free Church, was transferred to Aberdeen, where John attended Aberdeen Grammar School and enrolled in the study of medicine at the University of Aberdeen. At the University of Aberdeen, one of MacLeod's principal teachers was the young professor John Alexander MacWilliam. He was awarded his medical degree with honours in 1898 and then spent a year studying biochemistry at the University of Leipzig, Germany, on a travelling scholarship. He became a demonstrator at the London Hospital Medical School, where in 1902 he was appointed lecturer in biochemistry. In the same year, he was awarded a doctorate in public health from Cambridge University. Around that time he published his first research article, a paper on phosphorus content in muscles. In 1903, Macleod became a lecturer in physiology at the Western Reserve University in Cleveland, Ohio, where he remained for 15 years. This was the period when he developed an interest in carbohydrate metabolism that was to last for the rest of his career. In 1910, he delivered a lecture on various forms of experimental diabetes and their significance for diabetes mellitus at the joint meeting of the section on Pharmacology and Therapeutics and the section on Pathology and Physiology of the American Medical Association. In 1916, he was a Professor of Physiology at McGill University in Montreal, Canada.
=== Environmental triggers === Environmental factors, such as glandular viral infection, could prompt epithelial cells to activate the HLA-independent innate immune system through toll-like receptors. Although several infectious, exogenous agents have been implicated in the pathogenesis of Sjögren's disease, such as Epstein-Barr virus (EBV), human T-lymphotropic virus 1, and hepatitis C virus, their association with Sjögren's disease appears weak. While EBV is present in the salivary glands of normal individuals, a high incidence of EBV reactivation in Sjögren's patients has been reported with increased levels of EBV DNA. This indicates viral reactivation and the inability of lymphoid infiltrates to control EBV replication in Sjögren's disease, leading to the initiation or perpetuation of an immune response in target organs. Nonetheless, exactly how EBV reactivation is induced in lesions of patients with Sjögren's disease, and which specific molecular mechanisms are involved in the process of viral reactivation, remain to be clarified.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.